Top

DoW Breast Cancer, Clinical Research Extension Award

Active

Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The FY26 Breast Cancer Research Program Clinical Research Extension Award, solicitation number HT942526BCRPCREA2, is a grant opportunity issued by the Defense Health Agency Contracting Activity to support research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The program aims to recover knowledge lost due to early trial termination, limited patient follow-up, or suboptimal data collection. Eligible research includes deeper molecular analysis of clinical samples, continued clinical follow-up of patients from existing or completed trials, and the generation of molecularly characterized experimental platforms. Proposals to initiate new clinical trials or enroll new patients are explicitly prohibited. The application process is a two-tier system involving a pre-application and a full application, with a maximum period of performance of four years. Funding is capped at 7 million dollars for single PI applications. A distinctive requirement is the inclusion of two or more qualified breast cancer consumer advocates on the research team. The award allows for either a single Principal Investigator or a partnership between an Initiating PI and a Partnering PI. Applications are evaluated through a peer review for technical merit and a programmatic review for relevance, focusing on the research's impact on overarching breast cancer challenges and the feasibility of the scientific rationale. Applicants must be registered with an active status in SAM.gov and submit materials via Grants.gov or eBRAP. Required documentation includes a three-page Statement of Work, technical and lay abstracts, and specific biographical sketches for key personnel. The evaluation process places equal importance on the research impact, strategy, personnel expertise, and the integration of consumer advocates. Final funding recommendations are subject to approval by a designated official, and the inclusion of classified research data may lead to administrative withdrawal.

General Info

DHA grant for breast cancer clinical research extensions, capped at 7 million dollars.

Agency

Department Of Defense → Defense Health Agency Contracting Activity - Dhaca

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

Timeline

PostedAug 20

forecast

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Defense → Defense Health Agency Contracting Activity - Dhaca

Contacts1 person available

OfficeUSA

Organization / AgencyDepartment Of Defense → Defense Health Agency Contracting Activity - Dhaca

Office AddressUSA

Contacts

eBRAP Help Desk

contact@example.gov

+1 (555) 000-0000

Full Description

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical studies by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.

Distinctive Features:

• The research team must include two or more breast cancer consumer advocates.

• This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.